Population Health Sciences

You are here

Publications

Found 257 results
Author [ Title(Asc)] Type Year
Filters: First Letter Of Last Name is B  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E et al..  2020.  Prognostic value of the SPOP mutant genomic subclass in prostate cancer.. Urol Oncol.
Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E et al..  2020.  Prognostic value of the SPOP mutant genomic subclass in prostate cancer.. Urol Oncol.
Brown B, O'Donnell E, Casalino LP.  2019.  Private Equity Investment in Behavioral Health Treatment Centers.. JAMA Psychiatry.
Casalino LP, Saiani R, Bhidya S, Khullar D, O'Donnell E.  2019.  Private Equity Acquisition of Physician Practices.. Ann Intern Med. 171(1):78.
Sterling MR, Jannat-Khah D, Bryan J, Banerjee S, McClure LA, Wadley VG, Unverzagt FW, Levitan EB, Goyal P, Peterson JC et al..  2019.  The Prevalence of Cognitive Impairment Among Adults With Incident Heart Failure: The "Reasons for Geographic and Racial Differences in Stroke" (REGARDS) Study.. J Card Fail. 25(2):130-136.
Sterling MR, Jannat-Khah D, Bryan J, Banerjee S, McClure LA, Wadley VG, Unverzagt FW, Levitan EB, Goyal P, Peterson JC et al..  2019.  The Prevalence of Cognitive Impairment Among Adults With Incident Heart Failure: The "Reasons for Geographic and Racial Differences in Stroke" (REGARDS) Study.. J Card Fail. 25(2):130-136.
Cotton BP, Lohman MC, Brooks JM, Whiteman KL, Bao Y, Greenberg RL, Bruce ML.  2017.  Prevalence of and Factors Related to Prescription Opioids, Benzodiazepines, and Hypnotics Among Medicare Home Health Recipients.. Home Healthc Now. 35(6):304-313.
Cotton BP, Lohman MC, Brooks JM, Whiteman KL, Bao Y, Greenberg RL, Bruce ML.  2017.  Prevalence of and Factors Related to Prescription Opioids, Benzodiazepines, and Hypnotics Among Medicare Home Health Recipients.. Home Healthc Now. 35(6):304-313.
Cotton BP, Lohman MC, Brooks JM, Whiteman KL, Bao Y, Greenberg RL, Bruce ML.  2017.  Prevalence of and Factors Related to Prescription Opioids, Benzodiazepines, and Hypnotics Among Medicare Home Health Recipients.. Home Healthc Now. 35(6):304-313.
Kennel PJ, Kneifati-Hayek J, Bryan J, Banerjee S, Sobol I, Lachs MS, Safford MM, Goyal P.  2019.  Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES).. BMC Cardiovasc Disord. 19(1):76.
Kennel PJ, Kneifati-Hayek J, Bryan J, Banerjee S, Sobol I, Lachs MS, Safford MM, Goyal P.  2019.  Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES).. BMC Cardiovasc Disord. 19(1):76.
Kapadia SN, Bao Y.  2019.  Prescription painkiller misuse and the perceived risk of harm from using heroin.. Addict Behav. 93:141-145.
Bao Y, Pan Y, Taylor A, Radakrishnan S, Luo F, Pincus HAlan, Schackman BR.  2016.  Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians.. Health Aff (Millwood). 35(6):1045-51.
Wen H, Hockenberry JM, Jeng PJ, Bao Y.  2019.  Prescription Drug Monitoring Program Mandates: Impact On Opioid Prescribing And Related Hospital Use.. Health Aff (Millwood). 38(9):1550-1556.
Meinhofer A, Williams ARobin, Johnson P, Schackman BR, Bao Y.  2019.  Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 105:37-43.
Bao Y, Eggman AA, Richardson JE, Sheeran TF, Bruce ML.  2015.  Practices of Depression Care in Home Health Care: Home Health Clinician Perspectives.. Psychiatr Serv. 66(12):1365-8.
Bao Y, Eggman AA, Richardson JE, Sheeran TF, Bruce ML.  2015.  Practices of Depression Care in Home Health Care: Home Health Clinician Perspectives.. Psychiatr Serv. 66(12):1365-8.
Press MJ, Gerber LM, Peng TR, Pesko MF, Feldman PH, Ouchida K, Sridharan S, Bao Y, Barron Y, Casalino LP.  2015.  Post-Discharge Communication Between Home Health Nurses and Physicians: Measurement, Quality, and Outcomes.. J Am Geriatr Soc. 63(7):1299-305.
Press MJ, Gerber LM, Peng TR, Pesko MF, Feldman PH, Ouchida K, Sridharan S, Bao Y, Barron Y, Casalino LP.  2015.  Post-Discharge Communication Between Home Health Nurses and Physicians: Measurement, Quality, and Outcomes.. J Am Geriatr Soc. 63(7):1299-305.
Gupta A, Kesavabhotla K, Baradaran H, Kamel H, Pandya A, Giambrone AE, Wright D, Pain KJ, Mtui EE, Suri JS et al..  2015.  Plaque echolucency and stroke risk in asymptomatic carotid stenosis: a systematic review and meta-analysis.. Stroke. 46(1):91-7.
Jung H-Y, Unruh MAaron, Vest JR, Casalino LP, Kern LM, Grinspan ZM, Bao Y, Kaushal R.  2017.  Physician Participation in Meaningful Use and Quality of Care for Medicare Fee-for-Service Enrollees.. J Am Geriatr Soc. 65(3):608-613.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Batra JS, Niaz MJunaid, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM et al..  2020.  Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer.. Urol Oncol.